Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 3/20 | 0.71 |
| ▸ | PGK2 | P07205 | 3/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6328801 | 1.00 | PGK1 (0.71) | PGK1PGK2ADORA3ADORA1ADORA2A | |
| SCHEMBL5694965 | 0.91 | ADORA2A (0.58) | PGK1PGK2ADORA3ADORA1ADORA2A | |
| SCHEMBL5694961 | 0.91 | ADORA2A (0.58) | PGK1PGK2ADORA3ADORA1ADORA2A | |
| SCHEMBL7049149 | 0.86 | PGK1 (0.79) | PGK1PGK2ADORA3ADORA1ADORA2A | |
| SCHEMBL6332418 | 0.85 | ADORA2A (0.65) | ADORA3ADORA1ADORA2A | |
| SCHEMBL6332422 | 0.85 | ADORA2A (0.65) | ADORA3ADORA1ADORA2A | |
| SCHEMBL6328799 | 0.83 | ADORA3 (0.57) | ADORA3ADORA1ADORA2ANT5E | |
| SCHEMBL31201331 | 0.82 | ADORA1 (0.88) | PGK1PGK2ADORA3ADORA1ADORA2A | |
| SCHEMBL19370234 | 0.80 | ADORA3 (0.70) | PGK1PGK2ADORA3ADORA1ADORA2A | |
| SCHEMBL5695127 | 0.80 | ADORA2A (0.72) | ADORA3ADORA1ADORA2ANT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | claimed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | claimed |
| EP-1220863-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2003-04-23 | — | — | EP | claimed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | claimed |
| US-6350735-B1 | Purine derivatives | PFIZER INC | 2002-02-26 | — | — | US | claimed |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-11-10 | — | — | US | disclosed |
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-09-22 | — | — | US | disclosed |
| EP-1220863-B1 | PURINE DERIVATIVES | PFIZER LTD (GB) | 2003-04-23 | — | — | EP | disclosed |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-01-16 | — | — | US | disclosed |
| US-6350735-B1 | Purine derivatives | PFIZER INC | 2002-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209185-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | PGK1 3439/4885PGK2 2859/4885ADORA3 2/4885 |
| US-20030013675-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | PGK1 3376/4885PGK2 2135/4885ADORA3 2/4885 |
| US-20050250730-A1 | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases | ADORA2A, ADORA3, ADORA2B | PGK1 3439/4885PGK2 2859/4885ADORA3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.